A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Registration Number
- NCT05083169
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 587
- Documented multiple myeloma as defined by the criteria: a. multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria, b. measurable disease at screening as defined by any of the following: 1) serum M-protein level greater than or equal to (>=) 0.5 gram per deciliter (g/dL); or 2) urine M-protein level >=200 milligrams (mg)/24 hours; or 3) serum immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory. Stable disease or progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion
- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and prior to the start of administration of study treatment
- Have clinical laboratory values within the specified range
-
Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients. Additional exclusion criteria pertaining to specific study drugs include:
- A participant is not eligible to receive daratumumab subcutaneous (SC) in combination with pomalidomide and dexamethasone (DPd) as control therapy if any of the following are present: 1) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide, 2) Disease that is considered refractory to pomalidomide per IMWG,
- A participant is not eligible to receive daratumumab SC in combination with bortezomib and dexamethasone (DVd) as control therapy if any of the following are present: 1) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to bortezomib, 2) Grade 1 peripheral neuropathy with pain or Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, 3) Disease that is considered refractory to bortezomib per IMWG, 4) Received a strong cytochromes P450 (CYP3A4) inducer within 5 half-lives prior to randomization
-
Received any prior B cell maturation antigen (BCMA)-directed therapy
-
Has disease that is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody per IMWG
-
Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within 14 days before randomization
-
Received a live, attenuated vaccine within 4 weeks before randomization
-
Plasma cell leukemia at the time of screening, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary amyloid light chain amyloidosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Teclistamab-daratumumab (Tec-Dara) Daratumumab Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose. Arm A: Teclistamab-daratumumab (Tec-Dara) Teclistamab Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose. Arm B: DPd or DVd Daratumumab Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously. Arm B: DPd or DVd Pomalidomide Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously. Arm B: DPd or DVd Dexamethasone Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously. Arm B: DPd or DVd Bortezomib Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) Up to 5 years PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Overall Response (Partial Response [PR] or Better) Up to 5 years Overall response (PR or better) is defined as participants who have a PR or better per IMWG criteria.
Very Good Partial Response (VGPR) or Better Up to 5 years VGPR or better is defined as participants who achieve a VGPR or better response per IMWG criteria.
Complete Response (CR) or Better Up to 5 years CR or better is defined as participants who achieve a CR or better response per IMWG criteria.
Minimal Residual Disease (MRD)-negativity Up to 5 years MRD-negativity is defined as participants who achieve MRD negativity at a threshold of 10\^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy.
Progression Free Survival on Next-line Therapy (PFS2) Up to 5 years PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.
Overall Survival (OS) Up to 5 years OS is measured from the date of randomization to the date of the participant's death.
Time to Next Treatment (TTNT) Up to 5 years TTNT is defined as the interval time from randomization to the start of subsequent antimyeloma treatment.
Duration of Response Up to 5 years Duration of response will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG response criteria, or death due to any cause, whichever occurs first.
Number of Participants with Adverse Events (AEs) by Severity Up to 5 years Number of participants with AEs by Severity will be reported.
Serum Concentration of Teclistamab Up to 5 years Serum samples will be analyzed to determine concentrations of teclistamab using a validated, specific, and sensitive method.
Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab and Daratumumab Up to 5 years Number of participants with ADAs to teclistamab and daratumumab will be reported.
Time to Worsening of Symptoms Up to 5 years Time to worsening is measured as the interval from the date of randomization to the start date of meaningful change.
Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Baseline up to 5 years The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score Baseline up to 5 years The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Measurement Information System Short Form v2.0 - Physical Function 8c (PROMIS PF 8c) Baseline up to 5 years The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. Higher overall score indicates more sleep disturbance.
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ) Baseline up to 6 months The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L) Baseline up to 5 years The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient Global Impression - Severity (PGI-S) Baseline up to 5 years The PGIS contains 2 questions on how the participant would currently rate severity of symptoms and impacts with a 7-day recall period. The response options are presented as a 5-point verbal rating scale from 1="none" to 5="very severe."
PFS in Participants with High-risk Molecular Features Up to 5 years PFS in participants with high-risk molecular features will be reported.
Depth of Response in Participants in High-risk Molecular Features Up to 5 years Depth of response in participants in high-risk molecular features will be reported.
Trial Locations
- Locations (174)
Skanes universitetssjukhus
🇸🇪Lund, Sweden
Norrlands Universitetssjukhus
🇸🇪Umea, Sweden
Akademiska Sjukhuset
🇸🇪Uppsala, Sweden
Medipol University Hospital
🇹🇷Istanbul, Turkey
Dokuz Eylul University Medical Faculty
🇹🇷Izmir, Turkey
Blackpool Teaching Hospitals NHS Foundation Trust
🇬🇧Blackpool, United Kingdom
Ninewells Hospital & Medical School
🇬🇧Dundee, United Kingdom
Kings College Hospital
🇬🇧London, United Kingdom
Oxford University Hospitals NHS Foundation Trust
🇬🇧Oxford, United Kingdom
University Hospitals Plymouth NHS Trust
🇬🇧Plymouth, United Kingdom
Royal Marsden Hospital
🇬🇧Sutton, United Kingdom
Irmandade Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
🇧🇷Rio de Janeiro, Brazil
Hospital Sao Rafael
🇧🇷Salvador, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
🇧🇷Sao Paulo, Brazil
Hospital Paulistano
🇧🇷Sao Paulo, Brazil
Clinica Medica Sao Germano S/S LTDA
🇧🇷Sao Paulo, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷São Paulo, Brazil
Arthur J E Child Comprehensive Cancer Centre
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
First affiliated Hospital of Zhejiang University
🇨🇳Hangzhou, China
Zhongda Hospital Southeast University
🇨🇳Nanjing, China
First Affiliated Hospital of Guangxi Medical University
🇨🇳Nanning, China
Shanghai Zhongshan Hospital
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, China
Odense Universitets Hospital
🇩🇰Odense, Denmark
Vejle Hospital
🇩🇰Vejle, Denmark
CHU Henri Mondor
🇫🇷Creteil, France
CHRU de Lille Hopital Claude Huriez
🇫🇷LILLE Cedex, France
CHU de Limoges Hopital Dupuytren
🇫🇷Limoges, France
C.H.U. Hotel Dieu - France
🇫🇷Nantes, France
Centre hospitalier Lyon-Sud
🇫🇷Pierre Benite cedex, France
CHU De Poitiers
🇫🇷Poitiers, France
Institut de Cancerologie Strasbourg Europe ICANS
🇫🇷Strasbourg, France
Pôle IUC Oncopole CHU
🇫🇷Toulouse cedex 9, France
CHRU Hôpital Bretonneau
🇫🇷Tours, France
Universitätsklinikum Carl-Gustav-Carus Dresden
🇩🇪Dresden, Germany
Heinrich-Heine -Universitaet Duesseldorf
🇩🇪Düsseldorf, Germany
Evang. Krankenhaus Essen-Mitte gGmbH
🇩🇪Essen, Germany
Universitatsklinikum Freiburg
🇩🇪Freiburg, Germany
Universitaetsklinikum Hamburg Eppendorf
🇩🇪Hamburg, Germany
St. Barbara-Klinik Hamm GmbH
🇩🇪Hamm, Germany
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitaetsklinikum Schleswig Holstein Campus Kiel
🇩🇪Kiel, Germany
Universitaetsklinikum Leipzig
🇩🇪Leipzig, Germany
ASST Papa Giovanni XXIII Bergamo
🇮🇹Bergamo, Italy
Policlinico Sant'Orsola Malpighi
🇮🇹Bologna, Italy
Azienda Ospedaliera Universitaria Careggi
🇮🇹Firenze, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Sunderby Sjukhus
🇸🇪Luleå, Sweden
IRCCS Policlinico San Matteo, Università degli studi di Pavi
🇮🇹Pavia, Italy
Università di Roma 'La Sapienza' - Ospedale Umberto 1°
🇮🇹Roma, Italy
A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
🇮🇹Turin, Italy
Fukuoka University Hospital
🇯🇵Fukuoka, Japan
Ogaki Municipal Hospital
🇯🇵Gifu, Japan
National Hospital Organization Mito Medical Center
🇯🇵Higashiibaraki-gun, Japan
Tokai University Hospital
🇯🇵Isehara, Japan
Shonan Kamakura General Hospital
🇯🇵Kamakura-shi, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Dokkyo Medical University Saitama Medical Center
🇯🇵Koshigaya, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
National Hospital Organization Matsumoto Medical Center
🇯🇵Matsumoto, Japan
Inst. Cat. Doncologia-H Duran I Reynals
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. de Cabuenes
🇪🇸Gijón, Spain
Hosp. Univ. de Gran Canaria Dr. Negrin
🇪🇸Las Palmas de Gran Canaria, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. Ramon Y Cajal
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. Son Espases
🇪🇸Palma, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Quiron Madrid Pozuelo
🇪🇸Pozuelo de Alarcon, Spain
Hosp Clinico Univ de Salamanca
🇪🇸Salamanca, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
Hosp. Clinico Univ. de Santiago
🇪🇸Santiago de Compostela, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Hosp. Univ. I Politecni La Fe
🇪🇸Valencia, Spain
Falu Lasarett
🇸🇪Falun, Sweden
Sahlgrenska University Hospital
🇸🇪Göteborg, Sweden
Helsingborgs lasarett
🇸🇪Helsingborg, Sweden
Ondokuz Mayis University
🇹🇷Atakum, Turkey
S.P. Botkin Moscow City Clinical Hospital
🇷🇺Moscow, Russian Federation
Emory University Winship Cancer Institute
🇺🇸Atlanta, Georgia, United States
Clinical Research Institute of Hematology and Transfusiology
🇷🇺St-Petersburg, Russian Federation
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
University of Alabama Birmingham
🇺🇸Birmingham, Alabama, United States
City of Hope
🇺🇸Duarte, California, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
Yale University
🇺🇸New Haven, Connecticut, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Ascension Providence Hospital
🇺🇸Southfield, Michigan, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
West Penn Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Baptist Cancer Center
🇺🇸Memphis, Tennessee, United States
Vanderbilt Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
Fred Hutchinson Cancer Center
🇺🇸Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
Hospital Aleman
🇦🇷Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
🇦🇷Buenos Aires, Argentina
Hospital Privado Centro Medico de Cordoba
🇦🇷Cordoba, Argentina
ZNA Cadix
🇧🇪Antwerpen, Belgium
AZ St.-Jan Brugge-Oostende AV
🇧🇪Brugge, Belgium
UZ Gent
🇧🇪Gent, Belgium
Hopital de Jolimont
🇧🇪Haine Saint Paul La Louviere, Belgium
Az Groeninge
🇧🇪Kortrijk, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
Algemeen Ziekenhuis Delta
🇧🇪Roeselare, Belgium
Hospitais Integradaos da Gavea S/A - DF Star
🇧🇷Brasilia, Brazil
Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
🇧🇷Florianopolis, Brazil
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
BC Cancer Agency - Vancouver BC
🇨🇦Vancouver, British Columbia, Canada
QEII Health Sciences
🇨🇦Halifax, Nova Scotia, Canada
Princess Margaret Cancer Centre University Health Network
🇨🇦Toronto, Ontario, Canada
Peking University First Hospital
🇨🇳Beijing, China
Peking University People s Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun, China
The Third Xiangya Hospital of Central Sourth University
🇨🇳Changshashi, China
Beijing Chaoyang Hospital
🇨🇳Chaoyang District, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Fujian Meidical University Union Hospital
🇨🇳Fuzhou, China
Sun Yat Sen University Cancer Center
🇨🇳Guangzhou, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
The Second Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, China
The Affiliated Hospital of Xuzhou Medical University
🇨🇳Xuzhou, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Aalborg University Hospital
🇩🇰Aalborg, Denmark
Aarhus University Hospital
🇩🇰Aarhus N, Denmark
Rigshospitalet
🇩🇰Copenhagen, Denmark
Universitaetsklinikum Tuebingen
🇩🇪Tubingen, Germany
Alexandra General Hospital of Athens
🇬🇷Athens Attica, Greece
Anticancer Hospital of Thessaloniki Theageneio
🇬🇷Thessaloniki, Greece
G.Papanikolaou
🇬🇷Thessaloniki, Greece
U.O. Ematologia con Trapianto- AOU Policlinico di Bari
🇮🇹Bari, Italy
Nagoya City University Hospital
🇯🇵Nagoya, Japan
Hyogo Medical University Hospital
🇯🇵Nishinomiya shi, Japan
National Hospital Organization Okayama Medical Center
🇯🇵Okayama, Japan
National Hospital Organization Hiroshima-Nishi Medical Center
🇯🇵Otake, Japan
Hokkaido University Hospital
🇯🇵Sapporo-shi, Japan
National Hospital Organization Sendai Medical Center
🇯🇵Sendai-City, Japan
Tohoku University Hospital
🇯🇵Sendai, Japan
Japanese Red Cross Medical Center
🇯🇵Shibuya-ku, Japan
Iwate Medical University Hospital
🇯🇵Shiwa-gun, Japan
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Marys Hospital
🇰🇷Seoul, Korea, Republic of
VU Medisch Centrum
🇳🇱Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Sint Antonius Ziekenhuis - Afd.Interne - INT
🇳🇱Nieuwegein, Netherlands
Radboudumc
🇳🇱Nijmegen, Netherlands
Isala Kliniek
🇳🇱Zwolle, Netherlands
Klinika Hematologii i Transplantologii, UCK
🇵🇱Gdansk, Poland
Pratia Onkologia Katowice
🇵🇱Katowice, Poland
Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
🇵🇱Kielce, Poland
Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
🇵🇱Lublin, Poland
Specjalistyczny Szpital im dra Alfreda Sokolowskiego w Walbrzychu
🇵🇱Walbrzych, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
🇵🇱Wroclaw, Poland
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan